Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Allergy ; 71(9): 1345-56, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27184158

RESUMO

BACKGROUND: Specific allergen immunotherapy (SIT) is an effective allergy treatment, but it is unclear whether SIT is effective for atopic eczema (AE). We undertook a systematic review to assess SIT efficacy and safety for treating AE. METHODS: We searched databases, ongoing clinical trials registers, and conference proceedings up to July 2015. Randomized controlled trials (RCTs) of SIT using standardized allergen extracts, compared with placebo/control, for treating AE in patients with allergic sensitization were eligible. RESULTS: We identified 12 eligible trials with 733 participants. Interventions included subcutaneous (six trials), sublingual (four trials), oral or intradermal SIT in children/adults allergic to house dust mite (10 trials), grass pollen or other inhalants. Risk of bias was moderate, with high loss to follow-up and nonblinding as the main concerns. For our primary outcomes, three studies (208 participants) reported no significant difference - patient-reported global disease severity improvement RR 0.75 (95% CI 0.45, 1.26); and eczema symptoms mean difference -0.74 on a 20-point scale (95% CI -1.98, 0.50). Two studies (85 participants) reported a significant difference - SIT improved global disease severity RR 2.85 (95% CI 1.02, 7.96); and itch mean difference -4.20 on a 10-point scale (95% CI -3.69, -4.71). Meta-analysis was limited due to extreme statistical heterogeneity. For some secondary outcomes, meta-analyses showed benefits for SIT, for example investigator-rated improvement in eczema severity RR 1.48 (95% CI 1.16, 1.88; six trials, 262 participants). We found no evidence of adverse effects. The overall quality of evidence was low. CONCLUSION: We found no consistent evidence that SIT is effective for treating AE, but due to the low quality of evidence further research is needed to establish whether SIT has a role in AE treatment.


Assuntos
Dermatite Atópica/terapia , Dessensibilização Imunológica , Eczema/terapia , Alérgenos/imunologia , Terapia Combinada , Dermatite Atópica/diagnóstico , Dermatite Atópica/imunologia , Dessensibilização Imunológica/efeitos adversos , Dessensibilização Imunológica/métodos , Eczema/imunologia , Humanos , Viés de Publicação , Qualidade de Vida , Índice de Gravidade de Doença , Resultado do Tratamento
2.
Rev Cubana Med Trop ; 53(3): 217-21, 2001.
Artigo em Espanhol | MEDLINE | ID: mdl-15846927

RESUMO

Larval Echinococcus granulosus infection (hydatid cyst) was reported in a 10 years-old Ukranian girl. The clinical manifestations were slight since she only complained of frequent abdominal pain. The diagnosis was made by ultrasound and immunoenzymatic detection of antibodies to Echinococcus (ELISA). Antibody titers were 1/800. She was repeatedly treated with albendazol, and she managed to recover while the size of her cyst was reduced.


Assuntos
Equinococose/diagnóstico , Echinococcus granulosus , Animais , Criança , Feminino , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...